Nocturia - Pipeline Review, H2 2020

July 2020 | 45 pages | ID: N894AB22E78EN
Global Markets Direct

Abstracts

Nocturia - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nocturia - Pipeline Review, H2 2020, provides an overview of the Nocturia (Genito Urinary System And Sex Hormones) pipeline landscape.
Nocturia is defined as need to urinate at least twice during the night. This condition becomes more common as people age and occurs in both men and women, sometimes for different reasons. Causes of nocturia include congestive heart failure, edema of lower extremities, sleeping disorders such as obstructive sleep apnea, certain drugs, including diuretics (water pills), cardiac glycosides, demeclocycline, lithium, methoxyflurane, phenytoin, propoxyphene, and excessive vitamin d and drinking too much fluid before bedtime, especially coffee, caffeinated beverages, or alcohol. Treatment includes anticholinergic medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nocturia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Nocturia (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nocturia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 2 respectively.
Nocturia (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Nocturia (Genito Urinary System And Sex Hormones).
• The pipeline guide reviews pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Nocturia (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Nocturia (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Nocturia (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Nocturia - Overview
Nocturia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Nocturia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nocturia - Companies Involved in Therapeutics Development
Ferring International Center SA
Ferring Research Institute Inc
Roivant Sciences Ltd
Tacurion Pharma Inc
Wellesley Pharmaceuticals LLC
Nocturia - Drug Profiles
(acetaminophen + ibuprofen) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-7035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
desmopressin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nocturia - Dormant Projects
Nocturia - Discontinued Products
Nocturia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Nocturia, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Nocturia - Pipeline by Ferring International Center SA, H2 2020
Nocturia - Pipeline by Ferring Research Institute Inc, H2 2020
Nocturia - Pipeline by Roivant Sciences Ltd, H2 2020
Nocturia - Pipeline by Tacurion Pharma Inc, H2 2020
Nocturia - Pipeline by Wellesley Pharmaceuticals LLC, H2 2020
Nocturia - Dormant Projects, H2 2020
Nocturia - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Nocturia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Ferring International Center SA
Ferring Research Institute Inc
Roivant Sciences Ltd
Tacurion Pharma Inc
Wellesley Pharmaceuticals LLC